Shares of Tandem Diabetes Care encountered a decline of 2.5% during the afternoon trading session as news broke regarding a new competitor in the diabetes technology sector. Modular Medical, a newly established company founded by Paul DiPerna, the original founder of Tandem Diabetes in 2005, announced the first patient use of its Pivot tubeless insulin patch pump. This development raises considerations about increased competition in a substantial market segment.
The Pivot pump is targeted at insulin-dependent adults who rely on multiple daily injections—a demographic identified by Modular Medical as a large, underserved population, representing a multi-billion dollar market opportunity. The resurgence of Tandem’s founder in this new venture has heightened concerns among investors regarding potential market share erosion and increased rivalry in the market.
Following the announcement, Tandem’s stock dipped but later made a partial recovery, closing at $15.43, which marked a 2.5% decrease from its previous close. The volatility of Tandem Diabetes’s shares is notable, having experienced 51 fluctuations greater than 5% within the past year. This latest movement suggests that while the market views the news as significant, it does not necessarily alter the overall perception of Tandem’s business fundamentals.
A noteworthy event occurred approximately 29 days ago when Wells Fargo analysts upgraded the stock’s rating from Equal Weight to Overweight. They also elevated the price target from $21 to $27, highlighting a positive outlook on the company’s pharmacy channel following an informative meeting with Tandem’s management. Despite a challenging first quarter, where pharmacy results were somewhat disappointing, the company managed to rebuild its formulary coverage from virtually zero to about 40% in just one off-cycle quarter.
Looking ahead, preliminary data for the second quarter shows promise, with sales volume in April surpassing that of March, indicating positive momentum.
Year-to-date, Tandem Diabetes is down by 28.4%, and its current share price of $15.43 is 45.4% lower than its 52-week high of $28.26 from February 2026. To put this into perspective, an investment of $1,000 in Tandem’s shares five years ago would now be worth only $158.42, reflecting a significant loss for long-term investors.
